Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2023-185481

Published: 2023

Journal Articles

The Clinical Oncolytic Reovirus Formulation Reolysin Synergistically Augments the Anti-Leukemic Activity of Azacitidine

Rayna L Schwartz, Claudia Espitia, Dan O. Persky, Steffan T. Nawrocki, Jennifer S. Carew

Blood (2021) 138 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2021-151575

Published: 2021

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Shariful Islam, Claudia M Espitia, Ning Qu, MD PhD, Daniel Persky, MD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2018) 132 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2018-99-119152

Published: 2018

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Kevin R Kelly, MD PhD, Claudia M Espitia, Weiguo Zhao, Kaijin Wu, Valeria Visconte, PhD, Faiz Anwer, MD, Christine M Calton, PhD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2017) 130 (Supplement 1): 3137.

https://doi.org/10.1182/blood.V130.Suppl_1.3137.3137

Published: 2017

Journal Articles

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Kevin R. Kelly, MD PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Matt Coffey, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 3960.

https://doi.org/10.1182/blood.V128.22.3960.3960

Published: 2016

Journal Articles

Targeting Autophagy in Myelodysplastic Syndromes

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Bartlomiej P Przychodzen, MSc, Kevin R. Kelly, MD PhD, Mei Yin, Yvonne Parker, Michael J. Clemente, M.S., John Barnard, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Daniel Lindner, Heesun J Rogers, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4295.

https://doi.org/10.1182/blood.V128.22.4295.4295

Published: 2016

Journal Articles

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Valeria Visconte, PhD, Bartlomiej P Przychodzen, MSc, Steffan T. Nawrocki, PhD, Swapna Thota, MD, Kevin R. Kelly, MD PhD, Bhumika Patel, MD, Cassandra M. Hirsch, BSc, Hetty E. Carraway, MD MBA, Yvonne Parker, Daniel Lindner, Mikkael A. Sekeres, MD MS, Heesun J Rogers, MD PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4301.

https://doi.org/10.1182/blood.V128.22.4301.4301

Published: 2016

Journal Articles

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Valeria Visconte, PhD, James G Phillips, PhD, Bartlomiej P Przychodzen, MSc, Jaroslaw P Maciejewski, MD PhD FACP, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 525.

https://doi.org/10.1182/blood.V128.22.525.525

Published: 2016

Journal Articles

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Kevin R. Kelly, MD PhD, Kaijin Wu, PhD, Denice Tsao-Wei, Susan Groshen, Timothy Junius Triche, Jr., PhD, Ann Mohrbacher, Grace Chang, MD, Donna Fernando, Imran N Siddiqi, MD PhD, Matt Coffey, George Gill, Amy Lee, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 4507.

https://doi.org/10.1182/blood.V128.22.4507.4507

Published: 2016

Journal Articles

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Ronan LE Moigne, PhD, Valeria Visconte, PhD, Bartlomiej Przychodzen, MSc, Mark Rolfe, PhD, Stevan Djakovic, PhD, Daniel Anderson, David Wustrow, PhD, Han-Jie Zhou, Steve Wong, PhD, Anjali Advani, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1350.

https://doi.org/10.1182/blood.V126.23.1350.1350

Published: 2015

Journal Articles

Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Kevin R. Kelly, MD PhD, Yingchun Han, MD, Anthony Possemato, Sean Beausoleil, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1271.

https://doi.org/10.1182/blood.V126.23.1271.1271

Published: 2015

Journal Articles

Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy

Ahmad Zarzour, MD, Aziz Nazha, MD, Matt Kalaycio, MD, Bhumika J. Patel, Aaron T. Gerds, MD MS, Michael J. Clemente, Cassandra M Hirsch, Jennifer S. Carew, PhD, Anjali S. Advani, MD, Srinivasa R. Sanikommu, MBBS, Bartlomiej Przychodzen, MSc, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 1319.

https://doi.org/10.1182/blood.V126.23.1319.1319

Published: 2015

Journal Articles

Prognostic Impact of Molecular Mutations in AML at First Relapse

Anjali S. Advani, MD, Paul Elson, PhD, Valeria Visconte, PhD, Jennifer S. Carew, PhD, Jaime Fensterl, Bartlomiej Przychodzen, MSc, Mikkael A. Sekeres, MD MS, Cassandra M Hirsch, Alek Nielsen, John Desamito, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Sudipto Mukherjee, MD PhD, Ronald M. Sobecks, MD, Matt Kalaycio, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2015) 126 (23): 3825.

https://doi.org/10.1182/blood.V126.23.3825.3825

Published: 2015

Journal Articles

The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML)

Aziz Nazha, MD, Ahmad Zarzour, MD, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Jennifer S. Carew, PhD, Cassandra M Hirsch, Kassy E Kneen, Bartlomiej Przychodzen, MSc, Bhumika J. Patel, Michael Clemente, MS, Srinivasa R. Sanikommu, MBBS, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 86.

https://doi.org/10.1182/blood.V126.23.86.86

Published: 2015

Journal Articles

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2536.

https://doi.org/10.1182/blood.V126.23.2536.2536

Published: 2015

Journal Articles

Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma

Steffan T. Nawrocki, PhD, Claudia M. Espitia, Valeria Visconte, PhD, Yingchun Han, MD, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1807.

https://doi.org/10.1182/blood.V126.23.1807.1807

Published: 2015

Journal Articles

Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition

Jennifer S. Carew, PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Kevin R. Kelly, MD PhD, Steffan T. Nawrocki, PhD

Blood (2015) 126 (23): 3022.

https://doi.org/10.1182/blood.V126.23.3022.3022

Published: 2015

NARROW

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

The Clinical Oncolytic Reovirus Formulation Reolysin Synergistically Augments the Anti-Leukemic Activity of Azacitidine

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Targeting Autophagy in Myelodysplastic Syndromes

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy

Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy

Prognostic Impact of Molecular Mutations in AML at First Relapse

The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML)

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma

Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only